Benefit of IQP-AO-101 for Sleep
Primary Purpose
Insomnia, Nonorganic
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
IQP-AO-101
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Insomnia, Nonorganic
Eligibility Criteria
Inclusion Criteria:
- 21-65 years old
- Non-organic moderate sleep complaints in the last year prior to V1, as per investigator's judgement
- Pittsburgh Sleep Quality Index (PSQI) score 6-15 at V1
- Body mass index (BMI) 18.5-29.9 kg/m2
- Generally in good health without clinically significant findings at V1
Readiness to comply with study procedures, in particular:
- Consumption of the IP during the treatment period
- Wearing activity tracker during the scheduled time periods
- Filling in the subject diary
- Keeping habitual diet and level of physical exercise, as well as smoking habits if applicable
Women of child-bearing potential:
- Negative pregnancy testing (ß-HCG in urine) at V1
- Commitment to use reliable contraception methods during the entire study
- Written informed consent form
Exclusion Criteria:
- Known sensitivity to any components of the investigational product
- Insomnia (according to investigator's judgement))
- Substantial daily sleepiness as per investigator's judgement
- Less than 5 hours sleep per night on average, self-reported at V1
- Any medical condition associated with sleep disorder as per investigator's judgement (e.g. sleep apnoea, restless legs syndrome, neurological / psychiatric disorder)
- Any lifestyle and other factors potentially associated with sleep problems as per investigator's judgement (e.g. excessive caffeine intake, shift work, long-distance travelling, significant stressors such as active grieving etc.)
History and/or presence of clinically significant dis-ease, which per investigator's judgement could interfere with the results of the study or the safety of the subject:
- Eating disorders such as anorexia
- Untreated or non-stabilised metabolic diseases, e.g. diabetes mellitus
- Untreated or non-stabilised thyroid disorder
- Untreated or non-stabilised hypertension (regular systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg)
- Significant gastrointestinal diseases
- Any other known significant or serious condition / disease that renders subjects ineligible (e.g. history of malignancy within the past 5 years prior to V1, any clinically significant cardiovascular, renal, liver disease etc.)
- Use of drugs/supplements which could interfere with the results of the study as per investigator's judgement (e.g. melatonin and melatonin derivatives, stimulants, neuroleptics, benzodiazepines, antidepressants, hypnotics) within the last 4 weeks prior to V1 and during the study
- Behavioural intervention for sleep difficulties in the past 6 months and during the study as per investigator's judgement
Deviation of laboratory parameter(s) at V1 that is:
- clinically significant or
- >2x ULN (upper limit of normal), unless the deviation is justified by a previously known not clinically relevant condition, e.g. Gilbert's syndrome)
- Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Drug abuse
- Participation in another study during the last 4 weeks prior to V1 and during the study
- Women of child-bearing potential: pregnant or breast-feeding
- Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures
Sites / Locations
- Analyze & Realize
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
IQP-AO-101
Placebo
Arm Description
1 dose (sachet) to be consumed 30 - 60 mins before bedtime
1 dose (sachet) to be consumed 30 - 60 mins before bedtime
Outcomes
Primary Outcome Measures
Change in mAIS parameters at V5 vs V2
Change in modified Athens Insomnia Scale parameters
Secondary Outcome Measures
Change in mAIS parameter at V3 and V4, vs V2
Change in modified Athens Insomnia Scale parameters
Change in activity tracker sleep parameters
Use of an activity tracker to monitor sleep and compare against baseline
Change in FAIR-2
Change in FAIR-2 at each visit
Full Information
NCT ID
NCT03114696
First Posted
April 6, 2017
Last Updated
January 1, 2018
Sponsor
InQpharm Group
Collaborators
Analyze & Realize
1. Study Identification
Unique Protocol Identification Number
NCT03114696
Brief Title
Benefit of IQP-AO-101 for Sleep
Official Title
Double-blind, Placebo-controlled, Randomised Pilot Clinical Trial to Explore Benefit and Tolerability of IQP-AO-101 in Healthy Subjects With Sleep Complaints
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
April 25, 2017 (Actual)
Primary Completion Date
September 29, 2017 (Actual)
Study Completion Date
September 29, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
InQpharm Group
Collaborators
Analyze & Realize
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this pilot clinical trial is to evaluate the potential of IQP-AO-101 with respect to sleep-promoting effects in subjects with sleep complaints.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia, Nonorganic
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IQP-AO-101
Arm Type
Experimental
Arm Description
1 dose (sachet) to be consumed 30 - 60 mins before bedtime
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
1 dose (sachet) to be consumed 30 - 60 mins before bedtime
Intervention Type
Dietary Supplement
Intervention Name(s)
IQP-AO-101
Intervention Description
1 dose (sachet) to be consumed 30 - 60 mins before bedtime
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
Primary Outcome Measure Information:
Title
Change in mAIS parameters at V5 vs V2
Description
Change in modified Athens Insomnia Scale parameters
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Change in mAIS parameter at V3 and V4, vs V2
Description
Change in modified Athens Insomnia Scale parameters
Time Frame
1 week, 4 weeks
Title
Change in activity tracker sleep parameters
Description
Use of an activity tracker to monitor sleep and compare against baseline
Time Frame
1 week, 6 weeks
Title
Change in FAIR-2
Description
Change in FAIR-2 at each visit
Time Frame
1 week, 4 weeks, 6 weeks
Other Pre-specified Outcome Measures:
Title
Safety parameters assessed by number of subjects with abnormal laboratory values
Description
Number of subjects with abnormal laboratory values
Time Frame
1 week, 4 weeks, 6 weeks
Title
Adverse events that are related to treatment
Description
Monitoring of adverse effects
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
21-65 years old
Non-organic moderate sleep complaints in the last year prior to V1, as per investigator's judgement
Pittsburgh Sleep Quality Index (PSQI) score 6-15 at V1
Body mass index (BMI) 18.5-29.9 kg/m2
Generally in good health without clinically significant findings at V1
Readiness to comply with study procedures, in particular:
Consumption of the IP during the treatment period
Wearing activity tracker during the scheduled time periods
Filling in the subject diary
Keeping habitual diet and level of physical exercise, as well as smoking habits if applicable
Women of child-bearing potential:
Negative pregnancy testing (ß-HCG in urine) at V1
Commitment to use reliable contraception methods during the entire study
Written informed consent form
Exclusion Criteria:
Known sensitivity to any components of the investigational product
Insomnia (according to investigator's judgement))
Substantial daily sleepiness as per investigator's judgement
Less than 5 hours sleep per night on average, self-reported at V1
Any medical condition associated with sleep disorder as per investigator's judgement (e.g. sleep apnoea, restless legs syndrome, neurological / psychiatric disorder)
Any lifestyle and other factors potentially associated with sleep problems as per investigator's judgement (e.g. excessive caffeine intake, shift work, long-distance travelling, significant stressors such as active grieving etc.)
History and/or presence of clinically significant dis-ease, which per investigator's judgement could interfere with the results of the study or the safety of the subject:
Eating disorders such as anorexia
Untreated or non-stabilised metabolic diseases, e.g. diabetes mellitus
Untreated or non-stabilised thyroid disorder
Untreated or non-stabilised hypertension (regular systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg)
Significant gastrointestinal diseases
Any other known significant or serious condition / disease that renders subjects ineligible (e.g. history of malignancy within the past 5 years prior to V1, any clinically significant cardiovascular, renal, liver disease etc.)
Use of drugs/supplements which could interfere with the results of the study as per investigator's judgement (e.g. melatonin and melatonin derivatives, stimulants, neuroleptics, benzodiazepines, antidepressants, hypnotics) within the last 4 weeks prior to V1 and during the study
Behavioural intervention for sleep difficulties in the past 6 months and during the study as per investigator's judgement
Deviation of laboratory parameter(s) at V1 that is:
clinically significant or
>2x ULN (upper limit of normal), unless the deviation is justified by a previously known not clinically relevant condition, e.g. Gilbert's syndrome)
Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
Drug abuse
Participation in another study during the last 4 weeks prior to V1 and during the study
Women of child-bearing potential: pregnant or breast-feeding
Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures
Facility Information:
Facility Name
Analyze & Realize
City
Berlin
ZIP/Postal Code
10369
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31186669
Citation
Bongartz U, Tan BK, Seibt S, Bothe G, Uebelhack R, Chong PW, Wszelaki N. Sleep Promoting Effects of IQP-AO-101: A Double-Blind, Randomized, Placebo-Controlled Exploratory Trial. Evid Based Complement Alternat Med. 2019 May 2;2019:9178218. doi: 10.1155/2019/9178218. eCollection 2019.
Results Reference
derived
Learn more about this trial
Benefit of IQP-AO-101 for Sleep
We'll reach out to this number within 24 hrs